Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 29;92(S7):e2021524.
doi: 10.23750/abm.v92iS7.12396.

Use of remdesivir in children with COVID-19 infection: a quick narrative review

Andrea La Tessa  1 , Marco Antonio Motisi  1 , Gian Luigi Marseglia  2 , Fabio Cardinale  3 , Amelia Licari  2 , Sara Manti  4 , Mariangela Tosca  5 , Michele Miraglia Del Giudice  6 , Maria De Filippo  2 , Luisa Galli  1 , Elena Chiappini  7
Affiliations
Review

Use of remdesivir in children with COVID-19 infection: a quick narrative review

Andrea La Tessa et al. Acta Biomed. .

Abstract

SARS-CoV-2 infection has a severe course in a small percentage of children. Remdesivir has shown promising results in reducing hospitalisation time in adults, but data on mortality rate are conflicting and few studies are available on its use use in antivirals in children. We performed a quick narrative review of the available literature data regarding the usage of remdesivir in children and neonates. In children, remdesivir showed good safety profile, however bradicardia events have been reported in children. Remdesivir is currently recommended by several guidelines in some subgroups of children with severe COVID-19, and should also be considered in critically ill patients, always in the context of the overall clinical picture and drug availability.

PubMed Disclaimer

References

    1. Manti S, Licari A, Montagna L, et al. SARS-CoV-2 infection in pediatric population. Acta Biomed. 2020;91:e2020003. - PMC - PubMed
    1. Levy ER, Blumenthal J, Chiotos K., Coronavirus disease 2019 in children. Curr Opin Infect Dis . Epub ahead of print. 2021. - PubMed
    1. Garazzino S, Lo Vecchio A, Pierantoni L, et al. Epidemiology, clinical features and prognostic factors of pediatric SARS-CoV-2 infection: results from an italian multicenter study. Front Pediatr. 2021;9:649358. - PMC - PubMed
    1. Humeniuk R, Mathias A, Kirby BJ, et al. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of remdesi- vir, a SARS-CoV-2 replication inhibitor. Clin Pharmacoki- net . 2021;60:569–583. - PMC - PubMed
    1. Lutz JD, Mathias A, German P, Pikora C, Reddy S, Kirby BJ. Physiologically-based pharmacokinetic modeling of remdesivir and its metabolites to support dose selection for the treatment of pediatric patients with COVID-19. Clin Pharmacol Ther. 2021;109:1116–1124. - PMC - PubMed